MagnetisMM-4

Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma

What's the purpose of the trial?

The goal of this clinical trial is to evaluate the best dose, safety and effectiveness of elranatamab when combined with different anti-cancer therapies in participants with multiple myeloma.

Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
120
Last Updated
3 months ago
Am I Eligible

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma
  • Nirogacestat is a selective, reversible, non-competitive gamma-secretase inhibitor drug that is expected to increase the anti-tumor effectiveness of drugs like elranatamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Elranatamab + Nirogacestat

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.